Have a personal or library account? Click to login
A single centre experience with clinical use of Neria™ Guard as mode of pain and distress management in the administration of emicizumab in children Cover

A single centre experience with clinical use of Neria™ Guard as mode of pain and distress management in the administration of emicizumab in children

Open Access
|Dec 2024

Figures & Tables

A retrospective study finds the Neria™ Guard device to be effective in reducing pain and distress among children receiving treatment with emicizumab but recognises the need for further research and a validated, stability-tested solution
A retrospective study finds the Neria™ Guard device to be effective in reducing pain and distress among children receiving treatment with emicizumab but recognises the need for further research and a validated, stability-tested solution

Figure 1.

Photographs showing use of the Neria™ Guard device, which enables slow infusion during subcutaneous drug delivery
Photographs showing use of the Neria™ Guard device, which enables slow infusion during subcutaneous drug delivery

Figure 2.

Diagram showing component parts of the Neria™ Guard device
Diagram showing component parts of the Neria™ Guard device

j_jhp-2024-0019_utab_001

COMPONENT NUMBERCOMPONENTMATERIAL
1CylinderPolypropylene (PP)
2Fluid part basePolypropylene (PP)
3Septum (injection port)Silicone, Elastosil
4BushingPolycarbonate (PC)
5Introducer needleStainless steel, AiSi 304
6ReleaserPolyoxymethylene copolymer (POM)
7BaseCo-polyester
8Adhesive patchPolyester with polyacrylate adhesive
9Connector in grey colourMethyl methacrylate acrylonitrile butadiene styrene (MABS), Terlux 2802 HD, transparent, grey
10CoverPolypropylene (PP), grey
11Release buttonPolypropylene (PP), red
12LuerMethyl methacrylate acrylonitrile butadiene styrene (MABS), Terlux 2802 HD, transparent
13Connector needleStainless steel, AiSi 304
14Fixation tapeBandarole, Flexpeel
15Protective cap for connectorPolypropylene (PP)
16BlisterAmorphous polyethylene terephthalate/polyethylene (APET/PE)
17Blister lidMedical grade paper
18Extruder tube:Inner tubeOuter tubePolyethylene (PE)Polyurethane (PUR)
19Reinforcement liner(part of adhesive patch ID #8)Polyethylene terephthalate (PET) and acrylic adhesive
20Neeedle hubPolyoxymethylene (POM)
21Soft catheterPolytetrafluoroethylene (PTFE)
22PistonPolyoxymethylene copolymer (POM)
23Retraction springStainless steel spring wire (AiSi 302)
24Insertion springStainless steel spring wire (AiSi 302)
25Base lockPolypropylene (PP)
26N/AUV glue
27N/ASilicone oil

Serum emicizumab in the study population after initiation of Neria™ Guard

PATIENT NO.TREATMENT INTERVALDAYS FROM LAST INJECTION TO BLOOD SAMPLEDAYS FROM INITIATION OF NERIA™ GUARD TO BLOOD SAMPLEMEASURED EMICIZUMAB PLASMA LEVELS
1Every 14 days83653 μg/L
2Every 14 days29262 μg/L
3Every 14 days85433 μg/L
41 × week56171 μg/L
51 × week56141 μg/L
6Every 20 daysNo data available5652 μg/L
7Every 14 days15757 μg/L
8Every 14 days127265 μg/L
9Every 14 days127262 μg/L
10Every 14 days93748 μg/L
111 × week03549 μg/L
Language: English
Page range: 129 - 135
Published on: Dec 31, 2024
Published by: Haemnet Ltd
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2024 Maj Friberg Birkedal, published by Haemnet Ltd
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.